Compare WAFD & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | AAPG |
|---|---|---|
| Founded | 1917 | 2009 |
| Country | United States | China |
| Employees | 2037 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | WAFD | AAPG |
|---|---|---|
| Price | $30.84 | $22.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $31.90 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 531.0K | 1.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.15 | $368.64 |
| P/E Ratio | $11.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.75 | $17.56 |
| 52 Week High | $34.30 | $48.45 |
| Indicator | WAFD | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 38.04 |
| Support Level | $29.83 | N/A |
| Resistance Level | $31.78 | $26.01 |
| Average True Range (ATR) | 0.89 | 0.93 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 21.33 | 26.00 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.